Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib: A case report

Journal of Clinical Pharmacy and Therapeutics

Volumn 39, Issue 1, 2014, Pages 102-105

  Kaiafa, G ^a   Kakaletsis, N ^a   Savopoulos, C ^a   Perifanis, V ^a   Giannouli, A ^b   Papadopoulos, N ^c   Zisekas, S ^a   Hatzitolios, A I ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b THEAGENIO CANCER HOSPITAL   (Greece)

^c Euromedica Blue Cross Hospital   (Greece)

Author keywords

acute renal failure; adverse event; dasatinib; pleural effusion; simultaneous; tyrosine kinase inhibitor

Indexed keywords

ALANINE AMINOTRANSFERASE; ALLOPURINOL; AMLODIPINE; AMPICILLIN; ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; BISOPROLOL FUMARATE; DASATINIB; FUROSEMIDE; GLOBULIN; HEMOGLOBIN; IMATINIB; LEVOTHYROXINE SODIUM; METHYLPREDNISOLONE; NILOTINIB; POTASSIUM; PROTEIN; RABEPRAZOLE; SERUM ALBUMIN; SODIUM; SULBACTAM; UREA; URIC ACID;

ABNORMAL RESPIRATORY SOUND; ACUTE KIDNEY FAILURE; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTERIAL GAS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PH; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CARBON DIOXIDE TENSION; CASE REPORT; CHRONIC MYELOID LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FEVER; FOLLOW UP; GLOBULIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOTHYROIDISM; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MEDICAL HISTORY; MIDDLE AGED; NEUTROPHIL COUNT; OXYGEN TENSION; PERIORBITAL EDEMA; PLEURA EFFUSION; POTASSIUM BLOOD LEVEL; PROTEIN BLOOD LEVEL; RESPIRATORY TRACT INFECTION; SODIUM BLOOD LEVEL; THORACOCENTESIS; THORAX DRAINAGE; THORAX RADIOGRAPHY; THROMBOCYTE COUNT; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ACUTE RENAL FAILURE; ADVERSE EVENT; DASATINIB; PLEURAL EFFUSION; SIMULTANEOUS; TYROSINE KINASE INHIBITOR;

ACUTE KIDNEY INJURY; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; PLEURAL EFFUSION; PYRIMIDINES; THIAZOLES;

EID: 84891833043     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12107     Document Type: Article

References (37)

1. O'Hare T, Walters DK, Stoffregen EP, et al,. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res, 2005; 65: 4500-4505.
2. Tokarski JS, Newitt JA, Chang CY, et al,. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res, 2006; 66: 5790-5797.
3. Talpaz M, Shah NP, Kantarjian H, et al,. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med, 2006; 354: 2531-2541.
4. European Medicines Agency. Sprycel (dasatinib): summary of product characteristics [online]. Available at: http://www.ema.europa.eu (Accessed 13 February 2013).
5. Kantarjian H, Shah NP, Hochhaus A, et al,. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med, 2010; 362: 2260-2270.
6. Kantarjian H, Pasquini R, Hamerschlak N, et al,. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood, 2007; 109: 5143-5150.
7. Bergeron A, Rea D, Levy V, et al,. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med, 2007; 176: 814-818.
8. Hochhaus A, Kantarjian HM, Baccarani M, et al,. Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. Blood, 2007; 109: 2303-2309.
9. Wong SF,. New dosing schedules of dasatinib for CML and adverse event management. J Hematol Oncol., 2009; 2: 10.
10. Sonmez M, Cobanoglu U, Ovali E, Omay B,. Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance to imatinib and renal failure. J Clin Pharm Therap, 2008; 33: 329-330.
11. Masiello D, Gorospe G, Yang AS,. The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib. J Hematol Oncol, 2009; 2: 46.
12. Porkka K, Khoury HJ, Paquette RL, et al,. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer, 2010; 116: 377-386.
13. Kelly K, Swords R, Mahalingam D, et al,. Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. Target Oncol, 2009; 4: 99-105.
14. Andrae J, Gallini R, Betsholtz C,. Role of platelet-derived growth factors in physiology and medicine. Genes Dev, 2008; 22: 1276-1312.
15. Jayson GC, Parker GJ, Mullamitha S, et al,. Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol, 2005; 23: 973-981.
16. Goldblatt M, Huggins JT, Doelken P, et al,. Dasatinib-induced pleural effusions: a lymphatic network disorder? Am J Med Sc, 2009; 338: 414-417.
17. Bergeron A, Bergot E, Vilela G, et al,. Hypersensitivity pneumonitis related to imatinib mesylate. J Clin Oncol, 2002; 20: 4271-4272.
18. de Lavallade H, Punnialingam S, Milojkovic D, et al,. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol, 2008; 141: 745-747.
19. Shah NP, Kantarjian HM, Kim DW, et al,. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol, 2008; 26: 3204-3212.
20. Latagliata R, Breccia M, Fava C, et al,. Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. Hematol Oncol, 2012; 31: 363-369.
21. Quinta′s-Cardama A, Kantarjian H, O'Brien S, et al,. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol, 2007; 25: 3908-3914.
22. Kim D, Goh HG, Kim SH, et al,. Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy. Int J Hematol, 2011; 94: 361-371.
23. Kitiyakara C, Atichartakarn V,. Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571. Nephrol Dial Transplant, 2002; 17: 685-687.
24. Pou M, Saval N, Vera M, et al,. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. Leuk Lymphoma, 2003; 44: 1239-1241.
25. Foringer JR, Verani RR, Tjia VM, et al,. Acute renal failure secondary to imatinib mesylate treatment in prostate cancer. Ann Pharmacother, 2005; 39: 2136-2138.
26. François H, Coppo P, Hayman JP, et al,. Partial Fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss. Am J Kidney Dis, 2008; 51: 298-301.
27. Gafter-Gvili A, Rama R, Gafter U, et al,. Renal failure associated with tyrosine kinase inhibitors-Case report and review of the literature. Leukemia Res, 2010; 34: 123-127.
28. Vora A, Bhutani M, Sharma A, Raina V,. Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase. Ann Oncol, 2002; 13: 1833-1834.
29. Dann EJ, Fineman R, Rowe JM,. Tumor lysis syndrome after STI571 in Philadelphia chromosome-positive acute lymphoblastic leukemia. J Clin Oncol, 2002; 20: 354-355.
30. Ali R, Ozkalemkas F, Ozkan A, et al,. Tumour lysis syndrome with acute renal failure during imatinib therapy. Leuk Res, 2007; 31: 573-574.
31. Ozkurt S, Temiz G, Acikalin MF, Soydan M,. Acute Renal Failure under Dasatinib Therapy. Ren Fail, 2010; 32: 147-149.
32. Holstein SA, Stokes JB, Hohl RJ,. Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia. Leuk Res, 2009; 33: 334-347.
33. Christopher LJ, Cui D, Wu C, et al,. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos, 2008; 36: 1357-1364.
34. Lassila M, Jandeleit-Dahm K, Seah KK, et al,. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol, 2005; 16: 363-373.
35. Wang S, Wilkes MC, Leof EB, Hirschberg R,. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. Faseb J, 2005; 19: 1-11.
36. Sadanaga A, Nakashima H, Masutani K, et al,. Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice. Arthrit Rheum, 2005; 52: 3987-3996.
37. Zoja C, Corna D, Rottoli D, et al,. Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. Kidney Int, 2006; 70: 97-103.